Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

01. Manufacturer Patient Access Scheme (PAS) submitted by Celgene

02. Evidence Review Group critique of manufacturer PAS prepared by Kleijnen Systematic Reviews

03. Additional evidence provided by Celgene in response to Committee and NICE request for further cost-effectiveness analysis

04. ERG critique of additional evidence prepared by Kleijnen Systematic Reviews

05. Comments received from clinical expert Professor David Bowden

This page was last updated: 19 May 2014